end of compounded semaglutide The Semaglutide: Why the FDA's Decision Matters for Patients and Pharmacies - Seattle Plastic Surgery Compounded Semaglutide: Safety & Regulation

As of April 1, 2026, the FDA issued updated guidance stating that the GLP-1 supply is stabilizing and, with that, prohibiting pharmacies and outsourcing facilities from mass-producing copycat compounded versions of these medications

[1] These medications work by mimicking the action of naturally occurring GLP-1, a hormone released from the intestinal tract following food intake

The information presented reflects data available as of the publication date and may be updated as new research emerges

Eli Lilly's Retatrutide Advances Toward FDA Submission A major milestone in obesity treatment as Retatrutide (LY3437943) continues to demonstrate impressive Phase 3 results

Short light walks a few times a day assist with circulation and cut down on stiffness

A1C and fasting glucose